| July 24, 2014 | ISSUE NUMBER 361 VOL 4 |
Top Feature
Pharm Exec's 2014 Dealmakers Outlook
Dealmaking is today back to center stage, but with the major roles reversed— small biotech, yesterday's understudy, now gets top billing, while big Pharma has to work harder for its close-up. Pharm Exec brought partner Campbell Alliance and a select group of West Coast dealmakers to a Sonoma raceway for a test performance on what lies ahead for asset licensing and M&A activity in 2014 ...Read more
POP
Propel your education forward with the University of Florida’s online MS in Pharmaceutical Outcomes and Policy. Earn your master’s degree in as little as 2 years with collaborative online classes and flexible scheduling for working professionals. Focus on one of our three specializations, boost your high-level career opportunities, and cover topics affecting today’s pharmaceutical and regulatory environment. Learn more and apply by August 15: www.onlinepop.pharmacy.ufl.edu/
Europe
EFPIA's “Integrated Pharma Startegy”: Out of the Frying Pan and Into the Fire?
One of the most grandiose of the manifestos and strategy proposals from industry currently doing the rounds is EFPIA's self-styled “groundbreaking vision towards a life sciences strategy for Europe”. But the proposals could see EFPIA jumping out of the frying pan and into the fire, writes Reflector
...Read more
White Paper – Delivering the Value Message in the Language of Payers
At the heart of the changing healthcare environment are the payers, private and public, who are increasingly empowered to make decisions affecting which drugs and treatments are prescribed. inVentiv Health’s John Guarino explains that the decision-makers’ heightened focus on value demands an overhaul of traditional marketing and messages.  Read more
.
R&D
NIH Translational Research Partnership Yields Promising Therapy
A potential treatment for sickle cell disease has come through the “valley of death” of early stage development due to support from a collaborative partnership established by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). Jill Wechsler reports
...Read more
The lifecycle of a new product is shorter, more contested, full of regulatory delays, and beset by a challenging access and reimbursement environment. Learn how to wrest maximum value from every stage of the lifecycle – from access to acquisition to adherence—
 by downloading this eBook
Oncology
Breaking Point? The Cost of Cancer Care in the U.S.
The US healthcare system is expected to spend more than $150 billion treating cancer by 2020. Daniele Severi Bruni, Jacob J. Schutz, and Anthony Hewitt of ICON ask if we have we have hit a breaking point in the escalating cost of oncology care
...Read more
Seeing the Whole Picture: Harnessing the Power of Data to Drive Smarter Marketing Decisions
Thursday, August 7, 2014 at 1:00 PM EDT
To Registere at:
 www.pharmexec.com/picture
|
|
|
|
 //Viamet Pharmaceuticals (Research Triangle Park, NC) appointed Amir Tavakkol, Ph.D., as Chief Development Officer.//Peter Dansky became CEO of Agena Biosciences (San Diego, CA).//Neogen Corporation (Lansing, MI) announced that its Chief Operating Officer and President, Stephen Snyder, has resigned for personal reasons, effective July 31//Alexion Pharmaceuticals (Cheshire, CT) appointed David R. Brennan, M. Michele Burns and Christopher J. Coughlin to its Board of Directors.//
|
|
|
|
|
|
 |
|
|
| |
|
| |
|
 |
|
 |
The FDA Safety & Innovation Act (FDASIA) was signed into law two years ago. Where has the most progress been made in implementation?
|
|
|
|
